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Background: Associations between human leukocyte antigens (HLA) alleles and cervical
cancer are largely representative of squamous cell carcinoma (SCC), the major histologic
subtype.We evaluated the association between HLA class I (A, B, and C) and class II (DRB1
and DQB1) loci and risk of cervical adenocarcinoma (ADC), a less common but aggressive
histologic subtype.
Methods: We pooled data from the Eastern and Western US Cervical Cancer studies,
and evaluated the association between individual alleles and allele combinations and ADC
(n=630 ADC; n=775 controls). Risk estimates were calculated for 11 a priori (based on
known associations with cervical cancer regardless of histologic type) and 38 non a priori
common alleles, as odds ratios (OR) and 95% confidence intervals (CI), adjusted for age
and study. In exploratory analysis, we compared the risk associations between subgroups
with HPV16 or HPV18 DNA in ADC tumor tissues in the Western US study cases and
controls.
Results: Three of the a priori alleles were significantly associated with decreased risk
of ADC [DRB1*13:01 (OR=0.61; 95% CI: 0.41–0.93), DRB1*13:02 (OR= 0.49; 95% CI:
0.31–0.77), and DQB1*06:03 (OR=0.64; 95% CI: 0.42–0.95)]; one was associated with
increased risk [B*07:02 (OR=1.39; 95% CI: 1.07–1.79)]. Among alleles not previously
reported, DQB1*06:04 (OR=0.46; 95% CI: 0.27–0.78) was associated with decreased risk
of ADC and remained significant after correction for multiple comparisons, and C*07:02
(OR=1.41; 95% CI: 1.09–1.81) was associated with increased risk. We did not observe
a difference by histologic subtype. ADC was most strongly associated with increased
risk with B*07:02/C*07:02 alleles (OR=1.33; 95% CI: 1.01–1.76) and decreased risk with
DRB1*13:02/DQB1*06:04 (OR=0.41; 95% CI: 0.21–0.80).
Conclusion: Results suggest that HLA allele associations with cervical ADC are similar to
those for cervical SCC. An intriguing finding was the difference in risk associated with sev-
eral alleles restricted to HPV16 or HPV18-related tumors, consistent with the hypothesis
that HLA recognition is HPV type-specific.
Keywords: HLA class I, HLA class II, cervical adenocarcinoma, host genetics, HPV
INTRODUCTION
Cervical cancer is the second leading cause of cancer in women
world-wide, and infection with oncogenic human papillomavirus
(HPV) types is required for the development of these malignan-
cies. While HPV infections with oncogenic types are common
in women, only a small subset of infected individuals develop
cervical cancer for reasons not yet fully understood (1). There
are two major histologic subtypes of cervical cancer: cervical
adenocarcinomas (ADC), which constitute about 5–20% of all
cases and squamous cell carcinomas (SCC), which constitute the
majority of cases (2). Recent data from large pooled studies have
shown some risk factors, such as increasing number of lifetime
of partners and oral contraceptive use – are shared between the
two histologic subtypes (3, 4). Cigarette smoking is one risk
factor which has been consistently associated with an increased
risk of SCC but not ADC (5). While carcinogenic HPV infec-
tions are the central etiologic agents for both ADC and SCC,
there is divergence in HPV type detection in the two histologic
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subtypes, with HPV18 significantly more common in ADC than
in SCC (6).
In addition to known HPV cofactors, it is hypothesized that
host genetic factors play a significant role in susceptibility to
cervical precancer and cancer. Studies in Scandinavian coun-
tries, with well-established population registries, provide evi-
dence for familial aggregation in cervical cancer incidence (and
that of its immediate precursor, CIN3) (7–11). Those stud-
ies reported that cervical cancer risk associations are strongest
for full-relatives, intermediate for half-siblings, and lowest for
non-biological relatives.
Further evidence for genetic factors in cervical cancer is pro-
vided by studies that show associations with specific human
leukocyte antigens (HLA) alleles (12–20). The highly polymorphic
HLA molecules play a major role in immune response by present-
ing foreign antigens, including HPV peptides, to T lymphocytes,
thus promoting immune recognition and subsequent clearance
of infected cells (16). It is thought that HLA molecules that bind
HPV-specific antigens may be associated with protection from cer-
vical cancer, while HLA molecules that fail to recognize and present
HPV-specific antigens may be associated with increased cervical
cancer risk. Notably, a consistent inverse association has been
shown for the HLA DRB1*13:01-DQB1*06:03 haplotype, while
increased risks have been shown between HLA-B*07,DQB1*03:02,
and for DQB1*03:01 and cervical cancer (16, 20).
As SCC constitutes the major histologic type of cervical can-
cers, it remains unclear if HLA associations are different between
SCC and ADC. Two recent genome-wide association studies of
cervical cancer have identified strong associations between cer-
vical cancer and single nucleotide polymorphisms in 6p21.3, the
same region of the HLA loci (13, 14), however, one did not include
any ADC cases (14), and the other combined across SCC and ADC,
with no information on how many of each histologic type were
analyzed (13).
Our objective was to investigate HLA class I and II associations
with ADC using pooled data from two US case–control studies of
cervical cancer.
MATERIALS AND METHODS
STUDY POPULATION
We pooled data from two US case–control studies of cervical
cancer, one conducted by the Fred Hutchinson Cancer Research
Center (FHCRC): referred to here as the “Western US cervical can-
cer study”(20); and the other conducted by the US National Cancer
Institute: the “Eastern US cervical cancer study” (21). Briefly, the
Western US cervical cancer study enrolled women diagnosed with
in situ or invasive cervical ADC or invasive cervical SCC between
January 1986 and June 1998 or between January 2000 and Decem-
ber 2004. Case women were identified from the FHCRC-based
cancer surveillance system (CSS), a surveillance, epidemiology,
and end results (SEER) registry (22). In situ cases lived in the
13-county area of Western Washington State covered by the CSS
registry at the time of diagnosis, and invasive cases were limited to
those residing in the 3-county area that surrounded Seattle. Con-
trols were identified through random digit dialing (RDD), and
frequency matched to the cases by age (5 years strata) and area of
residence. In addition, control women with a hysterectomy were
excluded (n= 139). After restricting to women for whom there
was testing for HLA class I and II alleles, there were a total of 468
women with ADC (ICD-O morphology codes 8140–8561), 481
women with SCC (ICD-O morphology codes 8010–8077), and
513 controls in the Western US study (Figure S1 in Supplementary
Material).
The Eastern US cervical cancer study was a multi-center case–
control study, conducted between July 1994 and March 1996. Cases
were incident invasive primary cervical cancer identified from six
medical centers (George Washington University Medical Center,
Washington, DC; Georgetown University Medical Center, Wash-
ington, DC; Graduate Hospital, Philadelphia, PA; Hershey Medical
Center, Hershey, PA; University of Maryland Hospital, Baltimore,
MD; and Yale/New Haven Hospital, New Haven, CT) in the Eastern
US. Population controls were females (women with hysterectomies
were not eligible to be controls) identified through RDD, matched
to the cases (2:1) on age (5 year strata), clinic, race/ethnicity, and
telephone exchange. There were a total of 162 women with ADC
(ICD-O morphology codes 8140–8561), 179 women with SCC
(ICD-O morphology codes 8010–8077), and 262 controls in the
Eastern US study (Figure S1 in Supplementary Material).
HLA TESTING
Human leukocyte antigens class I and II loci were molecularly
typed with DNA extracted from buffy coat collected from each par-
ticipant as previously described (19, 20) using polymerase chain
reaction (PCR) and single-stranded oligonucleotide probe-based
protocols developed by the 13th International Histocompatibility
Workshop.
HPV TESTING
In the Western US cervical cancer study, HPV typing was per-
formed on tumor tissue blocks from cases using PCR–RFLP as
described in detail elsewhere (20); HPV DNA testing was not
available for controls in this study. MY09/11 L1 consensus primers
and HPV16 and HPV18 E6 type-specific primers were used with
co-amplification of the β-globin as a control for sample integrity.
In the Eastern US cervical cancer study, HPV typing was per-
formed on cervicovaginal cells (21) either self-collected using a
Dacron swab or clinician collected at the time of a pelvic exam
from cases and controls. Specimens were tested for presence of 27
HPV types using MY09/MY11 L1 consensus primer-based reverse
line blot PCR methods (23).
STATISTICAL METHODS
To increase homogeneity, we restricted the analytic sample to indi-
viduals of Caucasian ancestry (>85% of the study populations).
To address our primary objective of investigating HLA associa-
tions with cervical ADC, the final analytic sample comprised 630
ADC cases and 775 controls. Between the two studies, we identi-
fied 166 HLA class I and II alleles that were tested in both studies.
Only alleles with>5% prevalence in controls were included in the
main analyses (n= 49 alleles). Before the data were analyzed, we
searched PubMed and identified 11 “a priori” alleles that were
found to be significantly associated with cervical cancer in at
least two previously published peer-reviewed reports. Search terms
included HLA, cervical cancer, cervical SCC, cervical ADC, and
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included only studies that examined high-resolution HLA asso-
ciations with SCC or ADC in English. Reference lists of related
articles and recent review articles were also screened for additional
citations (Table S1 in Supplementary Material). We reasoned that
the HLA associations observed to date for SCC (or without regard
to histology) would also be observed for ADC.
We evaluated the association between the “a priori” set and the
remaining 38 alleles and ADC. Odds ratios (OR) and 95% con-
fidence intervals (95% CI) for the association between individual
alleles (modeled as two-level alleles; at least one allele present vs.
both alleles absent) and ADC risk were estimated using uncon-
ditional logistic regression and adjusting for study, and age at
diagnosis. For the 11 a priori set of alleles, we performed analy-
ses without adjustment for multiple comparisons. To adjust for
multiple comparison for the remaining 38 alleles, we adopted a
parametric bootstrap procedure to estimate the distribution of
the minimum p-value among the 38 tests, under the global null
hypothesis (24). A parametric bootstrap procedure was used to
generate null datasets under the null model, which is the reduced
logistic regression model without the effect from any HLA allele.
We also used the single-step method to obtain the adjusted p-value
for each of 38 testing alleles based on the estimated distribution of
the minimum p-value among the 38 tests.
We further investigated the association of our significant ADC
findings among SCC cases (n= 512) and controls available from
the pooled dataset. We reasoned that this comparison would allow
us to determine which, if any, allele associations are unique to
ADC. This investigation was carried out using polytomous logit
regression models to test the hypothesis that, for any particular
allele, the strength of the association differed between ADC and
SCC (test of homogeneity).
Give the differences in HPV cofactors noted between ADC and
SCC, in exploratory analysis, we examined whether HLA associ-
ations differed by HPV type detected in tumor tissue. Analyses
were restricted to either HPV16-related or HPV18-related ADC,
with each subset of the case group compared to all controls. To
ensure specificity, we restricted this analysis to the data available
from the Western US study, as in the Eastern US study for a large
fraction of cases, samples were collected after cervical cancer treat-
ment and thus HPV results do not reflect HPV type present at the
time of diagnosis, whereas cancer tissues were typed for presence
or absence of HPV in the Western US study. We excluded 26 ADC
cases with both HPV16 and HPV18 detected in the tumor tissue,
and used polytomous logit regression models to test the hypoth-
esis that, for any particular allele, the strength of the association
differed between HPV16 and HPV18 ADC (test of homogeneity).
Because of the lack of the control participant’s HPV status at the
time/age the case was infected (presumably soon after beginning
sexual activity, not at the time of cancer diagnosis) which is the
most ideal time for HPV exposure assessment (25), and because
HPV infections are very common, we believe that comparison with
all controls in the Western study, regardless of their current HPV
status, is appropriate.
Lastly, the joint effects of allele combinations were examined for
each of the statistically significant alleles. We constructed variables
to describe unphased combinations of significant alleles across the
loci. To examine the independent and combined effects of these
alleles on ADC risk, we constructed a categorical variable with
mutually exclusive groups of single and multiple alleles compared
to a reference group. The reference group comprised participants
that did not carry any of the alleles that were present in the com-
bination of interest. Two-sided statistical tests were performed at
α= 0.05 level. SAS version 9.1.3 was used for all analyses.
RESULTS
The Western US study consisted of 468 cervical ADC cases
(n= 311 in situ, n= 157 invasive) and 513 controls. The East-
ern US study consisted of 162 (n= 46 in situ, n= 116 invasive)
cervical ADC cases, and 262 controls (Figure S1 in Supplementary
Material).
Selected characteristics for cases and controls are presented in
Table S2 in Supplementary Material. Briefly, participants in the
Western US study were similar in age to the participants from the
Eastern US study (median age 39 vs. 38 years (interquartile range
32–48 vs. 30–45 years, respectively).
Table S3 in Supplementary Material presents HLA alleles with
frequencies of >5% among controls for alleles that were typed in
both studies. Out of the 166 alleles in both studies, 49 had frequen-
cies >5% among the controls. The allele frequencies were largely
similar across the two studies, with only seven of the allele frequen-
cies statistically significantly different between the two study popu-
lations. We therefore combined the cohorts in subsequent analyses.
Table 1A shows the main effects for the 11 pre-defined
HLA alleles. Three HLA class II alleles were associated with
a lower risk of ADC (ORDRB1*13:01= 0.61, 95% CI: 0.41–0.93;
ORDRB1*13:02= 0.49, 95% CI: 0.31–0.77; and ORDQB1*06:03= 0.64,
95% CI: 0.42–0.95). One class I allele was associated with increased
risk of ADC (ORB*07:02= 1.39, 95% CI: 1.07–1.79).
Of the remaining 38 alleles examined in Table 1B, we
observed a statistically significant decreased association with HLA-
DQB1*06:04 (OR= 0.46, 95% CI: 0.27–0.78) which retained sig-
nificance after adjustment for multiple comparisons (p= 0.02),
and an increased risk associations for HLA-C*07:02 (OR= 1.41,
95% CI: 1.09–1.81), which did not retain statistical significance
after adjustments for multiple comparisons (p= 0.09).
We also investigated the associations that were statistically sig-
nificantly associated with ADC in this analysis with risk of SCC in
data from the pooled studies (n= 660 SCC cases), and observed
that the associations for these HLA alleles, were similar between
the two histologic types as shown in Table 2. Associations between
all HLA alleles and SCC and ADC are presented in Table S4 in
Supplementary Material.
In exploratory analyses, we examined the association of HLA
alleles stratified by the case HPV status restricted to the West-
ern study as described in the Section “Materials and Meth-
ods.” Because we observed no differences in HLA allele asso-
ciations by histologic subtype, we combined ADC and SCC
cases for this analysis resulting in n= 302 HPV16 cases, n= 113
HPV18 cases, compared with N = 474 controls (Table 3). Four
alleles showed increased risk with HPV18-associated cancers
but decreased risk with HPV16-associated cancers (A*01:01
pheterogeneity= 0.0003, B*08:01 pheterogeneity= 0.003, B*15:01
pheterogeneity= 0.003 and DRB1*03:01 pheterogeneity= 0.01). None
of these alleles was associated with ADC in the analysis
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Table 1 | Association between 11 a priori selected HLA alleles (A), and remaining 38 non a priori HLA alleles (B) and cervical adenocarcinoma
(ADC) among Caucasians, PooledWestern and Eastern US cervical cancer studies.
(A)
ADC cases,
n=630
Controls,
n=775
Odds ratio
(95% CI)
p-Value
HLA-B
07:02 177 (28.1) 162 (20.9) 1.39 (1.07–1.79) 0.01
DRB1
04:01 118 (18.73) 131 (16.9) 1.12 (0.84–1.48) 0.43
11:01 55 (8.73) 57 (7.35) 1.28 (0.86–1.89) 0.23
13:01 39 (6.19) 73 (9.42) 0.61 (0.41–0.93) 0.02
13:02 28 (4.44) 66 (8.52) 0.49 (0.31–0.77) 0.002
15:01 166 (26.35) 173 (22.32) 1.20 (0.93–1.54) 0.16
DQB1
03:01 201 (31.9) 226 (29.16) 1.15 (0.91–1.46) 0.24
03:02 146 (23.17) 158 (20.39) 1.15 (0.88–1.49) 0.3
03:03 58 (9.21) 65 (8.39) 1.05 (0.72–1.53) 0.8
06:02 161 (25.56) 172 (22.19) 1.15 (0.89–1.48) 0.29
06:03 41 (6.51) 75 (9.68) 0.64 (0.42–0.95) 0.03
(B)
ADC cases,
n=630
Controls,
n=775
Odds ratio
(95% CI)
p Multiple
comparisons
HLA-A
01:01 178 (28.25) 192 (24.77) 1.03 (0.80–1.32)
02:01 267 (42.38) 321 (41.42) 0.86 (0.68–1.08)
03:01 158 (25.08) 155 (20) 1.25 (0.96–1.62)
11:01 60 (9.52) 76 (9.81) 0.90 (0.62–1.29)
24:02 106 (16.83) 100 (12.9) 1.31 (0.97–1.78)
29:02 44 (6.98) 48 (6.19) 0.98 (0.64–1.51)
31:01 36 (5.71) 33 (4.26) 1.24 (0.76–2.03)
32:01 43 (6.83) 46 (5.94) 1.07 (0.69–1.66)
68:01 40 (6.35) 50 (6.45) 0.91 (0.58–1.40)
HLA-B
08:01 123 (19.52) 151 (19.48) 0.87 (0.66–1.15)
15:01 69 (10.95) 80 (10.32) 0.99 (0.70–1.40)
18:01 42 (6.67) 50 (6.45) 0.97 (0.63–1.50)
27:05 38 (6.03) 58 (7.48) 0.73 (0.47–1.12)
35:01 62 (9.84) 78 (10.06) 0.90 (0.63–1.29)
40:01 57 (9.05) 72 (9.29) 0.89 (0.61–1.29)
44:02 106 (16.83) 108 (13.94) 1.14 (0.85–1.54)
44:03 55 (8.73) 57 (7.35) 1.09 (0.73–1.61)
51:01 42 (6.67) 59 (7.61) 0.76 (0.50–1.15)
57:01 49 (7.78) 48 (6.19) 1.14 (0.75–1.74)
HLA-C
01:02 34 (5.4) 39 (5.03) 1.01 (0.63–1.64)
02:02 46 (7.3) 60 (7.74) 0.87 (0.58–1.31)
03:03 63 (10) 58 (7.48) 1.23 (0.84–1.80)
03:04 81 (12.86) 102 (13.16) 0.87 (0.63–1.20)
04:01 114 (18.10) 125 (16.13) 1.09 (0.82–1.45)
05:01 87 (13.81) 109 (14.06) 0.90 (0.66–1.24)
06:02 113 (17.94) 124 (16) 1.02 (0.77–1.37)
07:01 156 (24.76) 199 (25.68) 0.84 (0.65–1.08)
(Continued)
(B)
ADC cases,
n=630
Controls,
n=775
Odds ratio
(95% CI)
p Multiple
comparisons
07:02 185 (29.37) 169 (21.81) 1.41 (1.09–1.81) 0.09
08:02 26 (4.13) 43 (5.55) 0.66 (0.40–1.10)
12:03 58 (9.21) 49 (6.32) 1.39 (0.93–2.09)
16:01 40 (6.35) 47 (6.06) 0.92 (0.59–1.44)
DRB1
01:01 104 (16.51) 110 (14.19) 1.18 (0.88–1.59)
03:01 135 (21.43) 175 (22.58) 0.89 (0.69–1.16)
04:04 66 (10.48) 65 (8.39) 1.27 (0.88–1.83)
07:01 138 (21.9) 178 (22.97) 0.93 (0.72–1.21)
08:01 28 (4.44) 40 (5.16) 0.81 (0.49–1.34)
DQB1
05:01 137 (21.75) 139 (17.94) 1.25 (0.96–1.64)
06:04 20 (3.17) 51 (6.58) 0.46 (0.27–0.78) 0.02
ADC, cervical adenocarcinoma; models adjusted for age and study.
Table 2 | Association between HLA alleles and cervical
adenocarcinoma (ADC) and squamous cell carcinoma (SCC), among
Caucasians, PooledWestern and Eastern US cervical cancer studies.
SCC cases
odds ratio (95%CI)
ADC cases
odds ratio (95%CI)
pheterogeneity
N =512 N =603
HLA-B
07:02 1.29 (1.00–1.68) 1.38 (1.1–1.78) 0.62
HLA-C
07:02 1.18 (0.91–1.53) 1.39 (1.1–1.79) 0.22
DRB1
13:01 0.74 (0.50–1.09) 0.61 (0.40–0.91) 0.39
13:02 0.52 (0.33–0.82) 0.48 (0.30–0.76) 0.78
DQB1
06:03 0.78 (0.53–1.14) 0.63 (0.42–0.94) 0.32
06:04 0.66 (0.41–1.07) 0.45 (0.26–0.76) 0.20
*p-Value for heterogeneity between SCC and ADC odds ratios from polyto-
mous regression models; models adjusted for age and study; reference category
is the pooled controls; SCC, cervical squamous cell carcinoma; ADC, cervical
adenocarcinoma.
of all HPV types combined (shown in Table 2). Four
alleles were associated with decreased risk of HPV18-
associated cancers but increased risk or no associations with
HPV16-associated cancers (DRB1*07:01 pheterogeneity= 0.001,
A*02:01 pheterogeneity= 0.006, C*05:01 pheterogeneity= 0.01, and
DRB1*04:01 pheterogeneity = 0.01).
Table 4 shows the results of the unphased allele combinations
that are in high linkage disequilibrium and found to be asso-
ciated with risk of ADC. We observed a statistically significant
elevated risk of ADC associated with carriers of HLA-B*07:02 and
HLA-C*07:02 (OR= 1.33, 95% CI: 1.01–1.76). We also observed
a statistically significant decreased risk of ADC associated with
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Table 3 | Association between HLA alleles and cervical cancer (regardless of histology) by HPV status, among Caucasians in theWestern cervical
cancer study.
HPV16 cases p HPV18 cases p pheterogeneity*
N =302 N =113
OR (95% CI) OR (95% CI)
HLA-A
01:01 0.80 (0.58–1.10) 0.17 1.82 (1.20–2.77) 0.005 0.0003
02:01 1.00 (0.75–1.34) 0.99 0.53 (0.35–0.82) 0.004 0.006
03:01 1.43 (1.03–1.97) 0.03 1.32 (0.83–2.09) 0.24 0.74
11:01 0.95 (0.60–1.50) 0.82 1.06 (0.57–1.98) 0.86 0.75
24:02 1.17 (0.78–1.74) 0.45 1.30 (0.75–2.24) 0.35 0.72
29:02 1.06 (0.63–1.80) 0.81 0.75 (0.32–1.73) 0.50 0.43
31:01 1.09 (0.58–2.02) 0.79 2.23 (1.11–4.50) 0.03 0.06
32:01 1.21 (0.70–2.12) 0.49 0.93 (0.40–2.17) 0.87 0.55
68:01 1.05 (0.60–1.84) 0.87 1.44 (0.70–2.95) 0.32 0.41
HLA-B
07:02 1.29 (0.93–1.78) 0.12 1.31 (0.84–2.06) 0.24 0.94
08:01 0.61 (0.43–0.88) 0.008 1.32 (0.84–2.06) 0.23 0.003
15:01 0.49 (0.29–0.84) 0.01 1.38 (0.78–2.46) 0.27 0.003
18:01 0.97 (0.56–1.68) 0.91 1.06 (0.50–2.27) 0.88 0.82
27:05 0.63 (0.35–1.13) 0.12 0.69 (0.30–1.59) 0.38 0.83
35:01 1.02 (0.65–1.62) 0.92 1.10 (0.59–2.07) 0.76 0.83
40:01 1.11 (0.71–1.71) 0.65 0.72 (0.36–1.46) 0.36 0.25
44:02 1.93 (1.33–2.78) 0.0005 1.10 (0.63–1.94) 0.74 0.05
44:03 1.41 (0.89–2.22) 0.15 0.62 (0.27–1.43) 0.26 0.06
51:01 1.05 (0.65–1.71) 0.83 0.52 (0.21–1.24) 0.14 0.12
57:01 1.44 (0.88–2.36) 0.15 0.77 (0.34–1.78) 0.54 0.15
HLA-C
01:02 0.79 (0.42–1.50) 0.47 1.47 (0.69–3.10) 0.32 0.15
02:02 0.91 (0.55–1.51) 0.70 0.64 (0.28–1.45) 0.28 0.42
03:03 0.70 (0.40–1.22) 0.21 1.40 (0.74–2.66) 0.31 0.06
03:04 0.84 (0.56–1.26) 0.40 0.81 (0.45–1.45) 0.49 0.91
04:01 1.01 (0.69–1.47) 0.96 1.00 (0.58–1.71) 0.995 0.97
05:01 1.45 (0.995–2.12) 0.053 0.61 (0.31–1.19) 0.14 0.01
06:02 1.17 (0.82–1.67) 0.38 0.69 (0.39–1.24) 0.21 0.08
07:01 0.74 (0.54–1.03) 0.07 1.08 (0.69–1.67) 0.74 0.12
07:02 1.28 (0.94–1.77) 0.12 1.29 (0.82–2.01) 0.27 0.99
08:02 0.49 (0.24–1.01) 0.054 0.66 (0.25–1.73) 0.40 0.59
12:03 0.89 (0.50–1.58) 0.69 1.78 (0.92–3.43) 0.09 0.06
16:01 1.30 (0.78–2.16) 0.31 0.66 (0.27–1.61) 0.36 0.14
DRB1
01:01 1.09 (0.74–1.59) 0.67 1.45 (0.87–2.42) 0.15 0.29
03:01 0.61 (0.43–0.86) 0.005 1.12 (0.71–1.75) 0.63 0.02
04:01 1.54 (1.11–2.14) 0.01 0.74 (0.42–1.30) 0.29 0.01
04:04 0.64 (0.37–1.10) 0.11 0.94 (0.46–1.92) 0.86 0.34
07:01 1.41 (1.03–1.92) 0.03 0.56 (0.32–0.96) 0.04 0.001
08:01 0.91 (0.50–1.67) 0.76 1.50 (0.71–3.16) 0.29 0.23
11:01 1.89 (1.13–3.15) 0.02 2.08 (1.05–4.13) 0.04 0.78
13:01 0.62 (0.37–1.03) 0.06 0.45 (0.19–1.08) 0.07 0.51
13:02 0.66 (0.38–1.14) 0.14 0.37 (0.13–1.04) 0.06 0.29
15:01 0.97 (0.71–1.33) 0.87 1.47 (0.96–2.26) 0.08 0.07
DQB1
03:01 1.33 (0.99–1.78) 0.06 1.07 (0.69–1.66) 0.77 0.36
03:02 0.91 (0.65–1.28) 0.60 0.90 (0.55–1.47) 0.66 0.94
(Continued)
HPV16 cases p HPV18 cases p pheterogeneity*
N =302 N =113
OR (95% CI) OR (95% CI)
03:03 1.59 (1.04–2.43) 0.03 0.99 (0.50–1.96) 0.97 0.18
05:01 1.05 (0.74–1.50) 0.77 1.42 (0.88–2.29) 0.15 0.24
06:02 0.89 (0.65–1.22) 0.47 1.41 (0.92–2.17) 0.12 0.05
06:03 0.64 (0.39–1.05) 0.07 0.51 (0.22–1.14) 0.10 0.60
06:04 0.75 (0.41–1.37) 0.35 0.24 (0.06–1.03) 0.06 0.14
*p-Value for heterogeneity between HPV16 and HPV18 odds ratios from polyto-
mous regression models. Polytomous regression used to estimate odds ratios
(OR) between HLA alleles and tumors containing HPV16 vs. HPV18 DNA; ref-
erence category are controls from the Western cervical cancer study. Models
adjusted for age.
HLA-DRB1*13:02 and DQB1*06:04 (OR= 0.41, 95% CI: 0.21–
0.80), and suggestive decreased risk for HLA-DRB1*13:01 and
DQB1*06:03 (OR= 0.62, 95% CI: 0.38–1.03). Evaluating these
combinations among SCC cases vs. controls revealed similar
patterns of association (data not shown).
DISCUSSION
Cervical ADC is less common than cervical SCC, comprising
between 5 to 20% of histologic subtype of cervical cancer depend-
ing on region (2), however, age-adjusted rates of ADC have
increased by ~32% over the past 35 years in the US, while they have
declined for SCC (26). This combined study represents the largest
study to examine the risk of ADC associated with HLA region loci.
Results from this pooled analysis of 630 ADC cases and 775 con-
trols affirmed findings from prior studies of cervical cancer that
largely represented SCC. We observed an increased ADC risk asso-
ciated with selected a priori alleles at B*07:02 and decreased ADC
risk with DRB1*13:01, DRB1*13:02, and DQB1*06:03. Among
new findings of this study, we identified a decreased risk of ADC
with HLA class II allele DQB1*06:04, which remained significant
after correction for multiple comparison. This allele has not been
reported in other studies that examined HLA associations with
cervical SCC or without regard to histologic type. The prevalence
of DQB1*06:04 was 7.2% in the combined control population
(6.6% in the Western and 8.8% in the Eastern study controls,
p> 0.05), and it was significantly correlated with DRB1*13:02
(correlation coefficient of 0.83, p< 0.0001), suggesting that the
inverse association we observed is likely due to linkage disequilib-
rium or its combination with DRB1*13:02, an allele that has been
reported to be inversely associated with cervical cancer in other
studies (20, 27).
Our data also strongly suggest that the associations we observed
between HLA alleles and ADC do not differ substantially from
those reported for SCC. The previously reported decreased asso-
ciation between SCC and HLA class II DRB1*13:01 was shown in
this study to also be associated with ADC (14, 15, 19, 27, 28). We
also showed the increased risk of class I HLA-B*07:02 with ADC
as shown with SCC (14, 27). Our observation that HLA associa-
tions were not different by histology indicates that with cervical
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Table 4 | Association between HLA allele combinations and cervical adenocarcinoma among Caucasians and pooledWestern and Eastern US
cervical cancer studies.
B*07:02 C*07:02 DRB1*13:01 DRB1*13:02 DQB1*06:03 DQB1*06:04 ADC cases (n=574) Controls (n=656) OR (95% CI)
– – – – – – 335 (58.36) 365 (55.64) 1.0 (Ref)
– C*07:02 – – – – 10 (1.74) 12 (1.83) 1.03 (0.44–2.45)
– – – DRB1*13:02 – – 7 (1.22) 14 (2.13) 0.54 (0.21–1.37)
B*07:02 C*07:02 – – – – 156 (27.18) 132 (20.12) 1.33 (1.01–1.76)
– – DRB1*13:01 – DQB1*06:03 – 28 (4.88) 55 (8.38) 0.62 (0.38–1.03)
– – – DRB1*13:02 – DQB1*06:04 13 (2.26) 36 (5.49) 0.41 (0.21–0.80)
B*07:02 C*07:02 DRB1*13:01 – DQB1*06:03 – 8 (1.39) 9 (1.37) 1.07 (0.40–2.88)
B*07:02 C*07:02 – DRB1*13:02 – DQB1*06:03 7 (1.22) 6 (0.91) 1.27 (0.42–3.87)
Model adjusted for age and study. Only combinations of over 1% in either cases or controls are shown in this table; “–” indicates absence of the respective allele(s).
cancer, HLA presentation of foreign peptides is independent of
histology. Further pooling of HLA results with other studies may
enable a more robust analysis of HLA types that recognize HPV
type-specific peptides, as our exploratory analysis of HPV16 vs.
HPV18 cervical cancer suggests (Table 3).
While the HPV type-specific analyses presented are based on
small sample size, it raises the possibility that specific HLA alle-
les could be mechanistically important in clearing or tolerance of
HPV infections. We note that our sample size was limited, thus our
findings could be due to false-positivity, and replication in other
settings is warranted.
We observed that increased risk of ADC was associated with
the combination of HLA B*07:02 and C*07:02, which is present
in over 15% of cases and controls. In addition, the correlation
coefficient for the two was 0.99, indicating that they are in high
linkage disequilibrium. We cannot determine if the increased risk
is associated more with one of these markers or if they together
may indicate risk of an untagged marker. Similarly, DRB1*13:02
and DQB1*06:04 were very rare (under 2%) by themselves, while
in combination, they occurred in over 2% of the cases and 5% of
the controls. This observation likewise indicates that the inverse
association may be due to the individual alleles, the combination of
alleles, or some marker in linkage with the combination of alleles.
The large sample size, well-characterized population-based
studies, and high-resolution molecular typing of HLA alleles are
substantial strengths of this analysis. There are several limita-
tions to be considered. The HLA genotyping was performed in
two different regions of the country, and genetic background
may be different. Even though we restricted to Caucasian ances-
try and controlled for study in the models, we may not have
eliminated residual confounding from population stratification.
Furthermore, it is possible that general laboratory differences
in practice and protocol could have led to the non-differential
misclassification of the exposure and thus the attenuation of asso-
ciations. Since both studies were restricted to those with Caucasian
ancestry, there may be different allele frequencies within different
geographic regions or subpopulations of the US. Even so, none of
the alleles identified as being statistically significantly associated
with ADC differed by study.
Another limitation was that, for the Western study, not all
biopsies or surgical tissues were available for HPV DNA typing
of tumor tissue. While we can assume most if not all cervical
cancer cases were HPV-positive for one or more carcinogenic
types (29–31), our HPV16/18 analyses are thus limited and need
replication.
In summary, pooling of these two studies provided a large sam-
ple size to assess the role of HLA on the risk of ADC, and provided
evidence that the HLA class I and II associations for ADC are sim-
ilar to those reported for SCC. Larger studies with detailed HPV
assessment coupled with high quality genetic data are needed to
further evaluate the effects of HLA and cervical ADC by HPV
genotype.
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